Drug Trial Radar · NCT06968962
Comparison of Sequential to Initial Combination Therapy in PAH
Last checked: Nov 20, 2026Latest source record: Jul 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
376
Planned (sponsor's estimate)
Start
May 14, 2025
Primary completion
May 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Huzhou Central Hospital; Ningbo Medical Center Lihuili Hospital; First Affiliated Hospital of Ningbo University; Ningbo No.2 Hospital; Affiliated Hospital of Jiaxing University; The Second Affiliated Hospital of Jiaxing University; First Affiliated Hospital of Wenzhou Medical University; Shanghai Pulmonary Hospital, Shanghai, China; Taizhou Hospital; Guangdong Provincial People's Hospital
- First posted
- May 13, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH patients is not inferior to the initial combination therapy as the primary efficacy endpoint is the change in 6MWD at month 12 from baseline.
Conditions
- Pulmonary Arterial Hypertension (PAH)
Interventions
TadalafilDrug
Target dose 40 mg OD
AmbrisentanDrug
Target dose 10 mg OD
Ambrisentan mimicDrug
Ambrisentan mimic will switch to Ambrisentan if low risk status was not achived at month 4, or 8, or 12.
Tadalafil mimicDrug
Tadalafil mimic will switch to Tadalafil if low risk status was not achived at month 4, or 8, or 12.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The change of 6MWD at month 12 from baselineTime frame: Baseline and Month 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.